Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Positron Corporation expects the evolution from cardiac SPECT to cardiac PET imaging will be greatly accelerated with the recent changes in reimbursement.

Positron Corporation, a molecular imaging solutions company focused on Nuclear Cardiology, expects the evolution from cardiac SPECT to cardiac PET imaging will be greatly accelerated with the recent changes in reimbursement from the Centers for Medicare & Medicaid Services (CMS) set for 2010.

The Medicare Physician Fee Schedule outlines the payment rates for medical services paid to private physicians in the outpatient office setting. This document states that Myocardial PET perfusion imaging was increased 20% to $1,432.87 per study. The Schedule also states that Cardiovascular SPECT reimbursement for outpatient cardiology practices billing under CPT codes has been reduced by 36% representing a differential of greater than $1,000 between tests.

Source: Positron Corporation

You can discuss more about Cardiology and related topics in our Cardiology Group.